Thermo Fisher Scientific Inc. (NYSE:TMO) and Innoforce have agreed to set up a new pharma services facility in Hangzhou, China for biologics and drug development and manufacturing. Innoforce is a Hangzhou, China-based contract development and manufacturing company. The two companies expect to complete the facility in 2022. The site will become part of Thermo Fisher’s…
Thermo Fisher to manufacture Inovio COVID-19 vaccine candidate
Inovio Pharmaceuticals (NSDQ:INO) announced that Thermo Fisher Scientific (NYSE:TMO) will manufacture its COVID-19 vaccine candidate. Plymouth Meeting, Pa.-based Inovio said in a news release yesterday that Thermo Fisher signed a letter of intent to manufacture the INO-4800 COVID-19 vaccine candidate, joining a consortium of third-party manufacturers that aim to produce 100 million doses of Inovio’s vaccine by 2021,…
Thermo Fischer Scientific to boost manufacturing for CSL
Thermo Fischer Scientific announced today that it has inked a strategic partnership with biotechnology company CSL to help better meet the growing demand for biologic therapies. Thermo Fisher will support CSL’s product portfolio through its pharma services network, including drug product development, biologics manufacturing, sterile fill-finish, packaging and clinical trials logistics. Thermo Fisher — through…